Frontiers in Immunology (Oct 2017)
Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2
- Xiao Tian,
- Xiao Tian,
- Xiao Tian,
- Xiao Tian,
- Feng Wei,
- Feng Wei,
- Feng Wei,
- Limei Wang,
- Limei Wang,
- Limei Wang,
- Wenwen Yu,
- Wenwen Yu,
- Wenwen Yu,
- Naining Zhang,
- Naining Zhang,
- Naining Zhang,
- Xinwei Zhang,
- Xinwei Zhang,
- Xinwei Zhang,
- Xinwei Zhang,
- Ying Han,
- Ying Han,
- Ying Han,
- Ying Han,
- Jinpu Yu,
- Jinpu Yu,
- Jinpu Yu,
- Xiubao Ren,
- Xiubao Ren,
- Xiubao Ren,
- Xiubao Ren
Affiliations
- Xiao Tian
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiao Tian
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiao Tian
- National Clinical Research Center of Cancer, Tianjin, China
- Xiao Tian
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Feng Wei
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Feng Wei
- National Clinical Research Center of Cancer, Tianjin, China
- Feng Wei
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Limei Wang
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Limei Wang
- National Clinical Research Center of Cancer, Tianjin, China
- Limei Wang
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Wenwen Yu
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Wenwen Yu
- National Clinical Research Center of Cancer, Tianjin, China
- Wenwen Yu
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Naining Zhang
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Naining Zhang
- National Clinical Research Center of Cancer, Tianjin, China
- Naining Zhang
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Xinwei Zhang
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xinwei Zhang
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xinwei Zhang
- National Clinical Research Center of Cancer, Tianjin, China
- Xinwei Zhang
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Ying Han
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ying Han
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ying Han
- National Clinical Research Center of Cancer, Tianjin, China
- Ying Han
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Jinpu Yu
- National Clinical Research Center of Cancer, Tianjin, China
- Jinpu Yu
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- Jinpu Yu
- Cancer Molecular Diagnostic Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiubao Ren
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiubao Ren
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiubao Ren
- National Clinical Research Center of Cancer, Tianjin, China
- Xiubao Ren
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
- DOI
- https://doi.org/10.3389/fimmu.2017.01426
- Journal volume & issue
-
Vol. 8
Abstract
Optimal adoptive cell therapy (ACT) should contribute to effective cancer treatment. The unique ability of natural killer (NK) cells to kill cancer cells independent of major histocompatibility requirement makes them suitable as ACT tools. Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2+ breast cancer. However, it has limited effectiveness and possible severe cardiotoxicity. Given that Herceptin may increase the cytotoxicity of lymphocytes, we explored the possible augmentation of NK cell cytotoxicity against HER2+ breast cancer cells by Herceptin. We demonstrated that Herceptin could interact with CD16 on NK cells to expand the cytotoxic NK (specifically, CD56dim) cell population. Additionally, Herceptin increased NK cell migration and cytotoxicity against HER2+ breast cancer cells. In a pilot study, Herceptin-treated NK cells shrunk lung nodular metastasis in a woman with HER2+ breast cancer who could not tolerate the cardiotoxic side effects of Herceptin. Our findings support the therapeutic potential of Herceptin-treated NK cells in patients with HER2+ and Herceptin-intolerant breast cancer.
Keywords
